{"version":"1.0","provider_name":"Frezza Partners","provider_url":"https:\/\/frezzapartners.com\/en\/","author_name":"Frezza Partners","author_url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/","title":"Accordo Gilead-Tango Therapeutics - Frezza Partners","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"JOEKCwOsmd\"><a href=\"https:\/\/frezzapartners.com\/en\/1012217\/\">Accordo Gilead-Tango Therapeutics<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/frezzapartners.com\/en\/1012217\/embed\/#?secret=JOEKCwOsmd\" width=\"600\" height=\"338\" title=\"&#8220;Accordo Gilead-Tango Therapeutics&#8221; &#8212; Frezza Partners\" data-secret=\"JOEKCwOsmd\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/frezzapartners.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/08\/hannah-busing-Zyx1bK9mqmA-unsplash1-scaled.jpg","thumbnail_width":2560,"thumbnail_height":1707,"description":"photo by Hannah Busing &nbsp; La strategia di Gilead \u00e8 continuare a puntare sull\u2019oncologia, e lo dimostrano anche le ultime scelte di business della societ\u00e0. Tre anni fa, John Milligan, AD di Gilead, aveva gi\u00e0 firmato un accordo con Tango Therapeutics, azienda biotech di Boston proprietaria di una tecnologia innovativa per sviluppare nuovi farmaci anti cancro. Ora, con il nuovo Ceo Daniel O&#8217;Da, l\u2019accordo viene ulteriormente confermato ed ampliato. Le due societ\u00e0 hanno infatti recentemente firmato un nuovo accordo del..."}